Abstract 2933: HSP90 inhibiting anti-cancer therapeutics enhance bone loss by increasing osteoclast formation: Mechanism of action.
A. Gabrielle J. van der Kraan(Monash Medical Centre), John T. Price(The University of Melbourne), Julian M.W. Quinn(Cancer Institute of New South Wales), Jiake Xu(Shenzhen Institutes of Advanced Technology), Michelle M. Kouspou(Monash University), Preetinder P. Singh, Ryan R. Chai(Monash University), Damien G. Eeles(La Trobe University), Benjamin Lang(Beth Israel Deaconess Medical Center), Matthew T. Gillespie(Hudson Institute of Medical Research)
Cited by 0
Related Papers
Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families
|Endocrine Reviews|1999|2.3k
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
|Journal of Clinical Investigation|1999|1.7k
Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation
|Nature Communications|2016|597
Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation1
|Endocrinology|1999|536
Heart disease prediction using supervised machine learning algorithms: Performance analysis and comparison
|Computers in Biology and Medicine|2021|482